Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autoantibodies in systemic sclerosis

D Vázquez-Abad1, N F Rothfield

  • 1Department of Medicine, University of Connecticut Health Center, Farmington 06030-1310, USA.

International Reviews of Immunology
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnosis of lupus erythematosus and rheumatoid arthritis in children.

Pediatric clinics of North America·2015
Same author

Centrosome proteins: a major class of autoantigens in scleroderma.

Journal of clinical immunology·1999
Same author

Treatment of severe Raynaud's phenomenon and ischemic ulcerations with tissue plasimogen activator.

Clinical and experimental rheumatology·1999
Same author

A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity.

Arthritis and rheumatism·1999
Same author

Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.

Clinical immunology (Orlando, Fla.)·1999
Same author

Anti-endothelial cell antibodies in systemic sclerosis: significant association with vascular involvement and alveolo-capillary impairment.

Clinical and experimental rheumatology·1998
Same journal

Leptin in metabolic-immune crosstalk: Mechanisms of T cell regulation and implications for autoimmune disease therapy.

International reviews of immunology·2026
Same journal

Metabolic alterations in the tumor microenvironment influence the anti-tumor immune function of CD8<sup>+</sup> T cells via epigenetic modifications.

International reviews of immunology·2026
Same journal

Macrophage markers and gene signature profiling reveals mesenchymal stem cells mediated immune modulation in Plasmodium berghei ANKA infection.

International reviews of immunology·2026
Same journal

Natural antigen landscape shaping intestinal Treg cells: Self, diet, and microbiota.

International reviews of immunology·2026
Same journal

Upregulation of ADAM10 reinforces CD8<sup>+</sup> T cells toward exhaustion in the TME.

International reviews of immunology·2026
Same journal

PTX3 promotes macrophage efferocytosis and inflammation resolution in granulomatous mastitis.

International reviews of immunology·2026
See all related articles

Three key autoantibodies, including anticentromere antibodies (ACA) and anti-topoisomerase I (anti-topo I), are specific to scleroderma subsets. These biomarkers aid in diagnosing and understanding scleroderma disease.

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmunity

Background:

  • Scleroderma is characterized by the presence of specific autoantibodies in patient sera.
  • Three major autoantibodies are identified: anticentromere antibodies (ACA), anti-topoisomerase I (anti-topo I), and anti-RNA polymerases.
  • These autoantibodies are mutually exclusive, each present in approximately 25% of scleroderma patients.

Purpose of the Study:

  • To delineate the specific autoantibodies associated with scleroderma.
  • To understand the distribution and exclusivity of these autoantibodies in scleroderma subsets.
  • To differentiate scleroderma-specific autoantibodies from those found in other conditions.

Main Methods:

  • Analysis of autoantibody profiles in sera from scleroderma patients.

Related Experiment Videos

  • Comparison of autoantibody prevalence in scleroderma versus other conditions like Raynaud's disease and primary biliary cirrhosis.
  • Characterization of autoantibody specificity and stability over time.

    • Main Results:

    • Anticentromere antibodies (ACA) are found in Raynaud's disease and primary biliary cirrhosis, in addition to scleroderma.
    • Anti-topoisomerase I (anti-topo I) and anti-RNA polymerases are exclusively found in scleroderma patients.
    • ACA and anti-topo I autoantibodies are stable over time, recognizing multiple epitopes and exhibiting stable idiotype profiles.

    Conclusions:

    • ACA, anti-topo I, and anti-RNA polymerases are specific biomarkers for distinct scleroderma patient subsets.
    • Anti-topo I and ACA are well-characterized, stable autoantibodies crucial for scleroderma diagnosis.
    • Other autoantibodies targeting nucleolar antigens are less prevalent and not specific to scleroderma.